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Introduction. Dysregulation of hepcidin, a key iron regulating hormone, is important in the pathogenesis of 
iron overload in patients with myelodysplatic syndromes (MDS), heterogeneous clonal myeloid disorders 
characterized by ineffective hematopoiesis, especially erythropoiesis, cytopenia and deregulated iron 
homeostasis. Recently, Erythroferrone (ERFE) was discovered as a new erythroid-regulator of hepcidin in 
the context of erythropoietic stress. ERFE, encoded in humans by the FAM132B gene, induces increased 
iron availability by downregulation of hepcidin in the liver and therefore represents an important new factor 
in iron homeostasis to be explored as a potential diagnostic or therapeutic target in the context of anemia 
and iron overload. In order to determine the specific role of ERFE in MDS, we analyzed the gene 
expression of FAM132B in MDS patients and controls and correlated the differential expression data with 
clinical parameters and expression level of others iron genes. 
Methods. Bone marrow samples from 65 newly diagnosed MDS and 8 non-malignant hematological 
patients were collected. The diagnosis of MDS was based on the 2008 World Health Organization (WHO) 
classification. Total RNA was extracted with Trizol reagent. Reverse transcription and PCR amplification 
were performed according to manufacturer’s instruction. The expression level of each gene was normalized 
to the housekeeping gene ABL1 and analyzed by 2-ΔΔCT relative quantitative method. Statistical analyses 
were performed using GraphPad 4.0 software. P-values of <0.05 were considered statistically significant. 
Unpaired t-test or Mann Whitney test was used to study difference between two groups. Correlation 
analysis was performed using the Spearman’s rank correlation coefficient rs. 
Results. We first evaluated the expression of FAM132B in total bone marrow (BM) cells of 65 newly 
diagnosed MDS patients. FAM132B expression had a more variable expression pattern in MDS than 
controls and was highly expressed in 31 out of 65 patients. In BM cells, expression levels of FAM132B 
correlated inversely with those of HAMP and positively with those of FPN1 and EPOR. We next evaluated 
FAM132B expression in the different subgroups of WHO classification. ERFE expression was significantly 
higher in RA (p=0.0013) and RAEB-1 (p=0.001) subtypes when compared with controls, but not in RAEB-
2 or in RCMD. To investigate the potential role of ERFE in a clinical setting, we next conducted 
Spearman’s correlation analysis on the mRNA expression of FAM132B and laboratory parameters. Our 
results showed that FAM132B was positively correlated with serum iron, ferritin, bone marrow 
erythroblasts and MCV and inversely correlated with peripheral RBC. 
Discussion and Conclusion. This study analyzes the FAM132B expression in MDS, clonal conditions of the 
bone marrow with impaired hematopoiesis, especially erythropoiesis. The observed high overexpression of 
FAM132B in MDS patients, its positive correlation with BM erythroblasts but its negative correlation with 
peripheral RBC might be related to an abnormal and ineffective erythropoiesis. Moreover, the inverse 
correlation between FAM132B and BM HAMP confirms that ERFE is able to modulate, through hepcidin 
suppression, the iron homeostasis, not only at systemic level as shown by the correlation with the 
laboratory markers of iron metabolism, but also at the BM level. These finding suggest that ERFE may play 
an important role in the physiopathology of the dysfunctional erythropoiesis and it could be assessed as 
new biomarker in MDS. 
